Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Jian Zhang and De-Yan Cao
Background: We aimed to investigate the clinical significance and biological roles of ARHGAP11A in lung adenocarcinoma (LUAD).
Methods: We firstly analyzed the expression level of ARHGAP11A in LUAD based on TCGA. Next, quantitative reverse transcription PCR (qRT-PCR) was performed to examine the expression level of ARHGAP11A in LUAD cell lines (A549, and Calu-3). After ARHGAP11A knockdown in A549 cells, cell counting kit-8 (CCK-8) and trans well assays were used to measure the proliferation and migration ability of A549 cells with or without ARHGAP11A silence. Western blotting was utilized to identify the underlying pathway through which ARHGAP11A silencing mediates biological roles in LUAD.
Results: ARHGAP11A was significantly over-expressed in LUAD tissues. Patients in the high ARHGAP11A expression subgroup experienced worse overall survival compared to the low expression subgroup. Univariate and multivariate analysis exhibited that ARHGAP11A was an independent prognostic predictor for LUAD. After ARHGAP11A silencing in A549 cells, cell proliferation rate, invasive and migratory capacity were observed to be inhibited. Remarkably, western blot results exhibited that reduction of ARHGAP11A remarkably inhibited the expression of ROCK, pLIMK2, and pCofilin in A549 cells.
Conclusion: Increased ARHGAP11A expression could regulate LUAD cell proliferation and metastasis, and identified it as a poor prognostic biomarker in LUAD.